NCT04019327 is a Phase 1, PHASE2 clinical trial of Talazoparib in Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Who is sponsoring NCT04019327?

NCT04019327 is sponsored by Memorial Sloan Kettering Cancer Center.

What drugs are being tested in NCT04019327?

Interventions in NCT04019327: Talazoparib, Temozolomide.

What condition does NCT04019327 study?

NCT04019327 studies Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm, Prostate Cancer Metastatic, Castration-resistant Prostate Cancer.

Is NCT04019327 still recruiting?

NCT04019327 is currently completed. Last updated 15 December 2025.

Last reviewed 2025-12-15 · How we verify

NCT04019327

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer

Completed Phase 1, PHASE2 Last updated 15 December 2025

What this trial tests

Phase 1, PHASE2 trial testing Talazoparib in Prostate Cancer in 16 participants. Completed in 4 December 2025.

Timeline

11 July 2019

Primary endpoint
4 December 2025

4 December 2025

Quick facts

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	11 July 2019
Primary completion	4 December 2025
Estimated completion	4 December 2025
Sites	9 locations across United States

Drugs / interventions tested

Talazoparib (talazoparib) — full drug profile →
Temozolomide (temozolomide) — full drug profile →

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →
Prostate Adenocarcinoma — all drugs for Prostate Adenocarcinoma →
Prostate Neoplasm — all drugs for Prostate Neoplasm →
Prostate Cancer Metastatic — all drugs for Prostate Cancer Metastatic →

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

18 and older, male only, with Prostate Cancer or Prostate Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine what the safest dose of talazoparib plus temozolomide for participants with metastatic castration resistant prostate cancer. The purpose of Phase II is to test the efficacy (effectiveness) of talazoparib and temozolomide at the maximum tolerated dose, which was determined to be 1mg talazoparib and 75mg/m² temozolomide in the Phase Ib portion of this study.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities.
Jurkovicova D, Neophytou CM, Gašparović AČ, Gonçalves AC. · · 2022 · cited 95× · PMID 36499000 · DOI 10.3390/ijms232314672
BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications.
Messina C, Cattrini C, Soldato D, Vallome G, et al · · 2020 · cited 87× · PMID 32963528 · DOI 10.1155/2020/4986365
Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
Lozano R, Castro E, Aragón IM, Cendón Y, et al · · 2021 · cited 81× · PMID 33106584 · DOI 10.1038/s41416-020-01114-x
PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
Nizialek E, Antonarakis ES. · · 2020 · cited 58× · PMID 32982407 · DOI 10.2147/cmar.s227033
PARP inhibitors in metastatic prostate cancer.
Taylor AK, Kosoff D, Emamekhoo H, Lang JM, et al · · 2023 · cited 50× · PMID 37168382 · DOI 10.3389/fonc.2023.1159557
PARP inhibitor combinations in prostate cancer.
Pezaro C. · · 2020 · cited 28× · PMID 32215055 · DOI 10.1177/1758835919897537
Targeting treatment options for castration-resistant prostate cancer.
Miller DR, Ingersoll MA, Teply BA, Lin MF. · · 2021 · cited 20× · PMID 33816699
Androgen Receptor Signaling Inhibition in Advanced Castration Resistance Prostate Cancer: What Is Expected for the Near Future?
Pozas J, Álvarez Rodríguez S, Fernández VA, Burgos J, et al · · 2022 · cited 16× · PMID 36551557 · DOI 10.3390/cancers14246071

Verify or expand the search:

Other trials of Talazoparib

Trials testing the same drug.

NCT05873192 — Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer · Phase 2 · recruiting
NCT06762808 — Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC · Phase 2 · withdrawn
NCT06218628 — Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition · Phase 1 · recruiting
NCT05071937 — ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer · Phase 2 · recruiting
NCT05327010 — Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tu · Phase 2 · recruiting

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04019327 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
Last refreshed: 15 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04019327.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing